Iovance Biotherapeutics (IOVA) EBITDA Margin (2023 - 2026)
Iovance Biotherapeutics' EBITDA Margin was -42.70% in Q2 2026, up 131.90 percentage points from -174.60% a year earlier and up 58.81 percentage points from the prior quarter.
Powered by 
Analysis
Iovance Biotherapeutics (IOVA) EBITDA Margin (2023 - 2026) Analysis & Trends
On a trailing twelve-month basis, Iovance Biotherapeutics' EBITDA Margin was -81.36% through Jun 30, 2026, up 72.26 percentage points year-over-year; for FY2025, it was -139.44%, up 78.55 percentage points from FY2024.
- In earlier years, EBITDA Margin was -217.98% in FY2024 (+36715.74 pp) and -36933.73% in FY2023.
- The Q2 2026 figure marks the highest quarterly EBITDA Margin in data going back to Q2 2023.
- Compared with a year earlier, EBITDA Margin has increased for nine straight quarters, with an average year-over-year change of +7856.51 percentage points over the last eight quarters.
- Over the past five years, the year-over-year gain in EBITDA Margin ranged from 10.23 percentage points (Q3 2025) to 43937.51 percentage points (Q2 2024).
- Per Business Quant data, IOVA's EBITDA Margin in the three quarters before Q2 2026 was -101.50% (Q1 2026), -73.25% (Q4 2025) and -127.36% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 53.49% |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 35.95% |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 49.01% |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 6.02% |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 33.11% |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 46.01% |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | -124.26% |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 39.16% |
| 10 | Iovance Biotherapeutics | 6.61 Bn | 5.40 Bn | 55.72 Mn | -42.70% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -42.70% |
| Mar 31, 2026 | -101.50% |
| Dec 31, 2025 | -73.25% |
| Sep 30, 2025 | -127.36% |
| Jun 30, 2025 | -174.60% |
| Mar 31, 2025 | -229.41% |
| Dec 31, 2024 | -98.55% |
| Sep 30, 2024 | -137.59% |
| Jun 30, 2024 | -300.31% |
| Mar 31, 2024 | -15,397.06% |
| Dec 31, 2023 | -23,733.82% |
| Sep 30, 2023 | -23,765.67% |
| Jun 30, 2023 | -44,237.82% |
API Access
Iovance Biotherapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=IOVA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "IOVA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=IOVA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();